Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous regulatory T Cell Product (Guy's and St Thomas' NHS Foundation Trust)
- Development stage
- Phase 2
- Lead developer
- Guy's and St Thomas' NHS Foundation Trust
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
This autologous cell therapy consists of polyclonal naturally occurring regulatory T cells (nTregs) that are isolated from a patient and expanded ex vivo. Developed by Guy's and St Thomas' NHS Foundation Trust in collaboration with King's College London, the product is intended to prevent graft rejection in living-donor kidney transplant recipients. The therapy works by modulating the recipient's immune system to favor graft tolerance, potentially allowing for a reduction in standard maintenance immunosuppression. In clinical trials (notably 'The ONE Study'), the infusion of these cells post-transplantation was shown to be safe and associated with high rates of rejection-free survival compared to standard care.
- Other names
- nTreg therapyAutologous naturally occurring regulatory T cellsPolyclonal regulatory T cell therapy
02
Targets
NeuraminidaseIL-2 (Interleukin 2)
Beyond the preview
Go deeper on Autologous regulatory T Cell Product (Guy's and St Thomas' NHS Foundation Trust).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous regulatory T Cell Product (Guy's and St Thomas' NHS Foundation Trust).